Cytogen Corp. of Princeton, N.J., also reported safe repeat administration of itscolorectal cancer imaging agent. In a multicenter study led by Hani Nabi of the StateUniversity of New York in Buffalo, OncoScint Colorectal was repeatedly given to 95patients, with some receiving four or more infusions. The agent detected lesions in 30 of38 patients with known disease and produced HAMA responses in 34 percent of patients.
“Statistically, the overall sensitivity and adverse effect rate (2.1 percent) uponrepeat infusion in this study were virtually identical to the sensitivity and adverseeffect rate seen in earlier studies involving only single infusions of OncoScint,“Nabi said.
Cytogen (NASDAQ:CYTO) is seeking expanded FDA approval for OncoScint Colorectal to beused in repeated administrations.